Table 5.
Pharmacokinetic parameters of lenalidomide obtained by noncompartmental analysis
| Dose (mg) |
n | Tmax (hr) | Cmax (ng/ml) | AUC (ng·hr/ml) | CL/F (mL/min) | V/F (L) | T1/2 (hr) | Urine excretion, %dose* |
|---|---|---|---|---|---|---|---|---|
| 5 | 2 | 0.75 (0.5, 1) | 80 (66, 93) | 302 (257, 346) | 282 (240, 324) | 63.7 (59.7, 67.7) | 2.7 (2.1, 3.3) | - |
| 10 | 6 | 1 (0.5– 4) | 107 (59–163) | 571 (256–1415) | 388 (118–650) | 108.9 (48.7–236) | 3.1 (2.4–4.2) | - |
| 15 | 3 | 2 (1–4) | 195 (174–224) | 1090 (712–1391) | 248 (180–352) | 76.6 (57.4–99) | 2.9 (1.9–2.9) | - |
| 20 | 9 | 1 (0.5–6.1) | 343 (64–621) | 1901 (239–4093) | 351 (82–1395) | 90.4 (32.1–346) | 3.1 (1.9–7.8) | - |
| 25 | 6 | 1.5 (0.5–8.9) | 451 (311–631) | 3820 (1081–11363) | 192 (37–385) | 57.9 (39.4–91.1) | 5.3 (1.6–15.9) | - |
| 30 | 8 | 1.5 (0.5–6) | 593 (69–1315) | 4040 (844–15445) | 224 (32–593) | 95.2 (30.3–268) | 4.0 (3.2–14.2) | 47.0 (36.3–62.0) |
| 35 | 6 | 1 (0.5–4) | 782 (594–969) | 5309 (3172–7062) | 117 (83–183) | 70.6 (33.0–95.3) | 6.7 (3.7–14.5) | 54.6 (48.3–63.1) |
| 40 | 3 | 1 (0.75–2) | 842 (648–1002) | 3926 (3281–4656) | 173 (143–203) | 62.1 (21.7–92.7) | 4.1 (1.8–6.2) | 44.9 (43.8, 46.0) |
Values are presented as mean with the range in the bracket
*
Number of subjects used in calculation of urine excretion: 30 mg (n=3), 35 mg (n=4), and 40 mg (n=2)